ProGear + Oxafence Masks Receive FDA Clearance and Launch in U.S. Healthcare
Grand Challenges Annual Meeting to Include MB Presentation
Singletto to Partner with Kenyan Healthcare Organizations on TB Research
Singletto Launches ProGear+Oxafence Masks in New Zealand
aPDI Method Proven Effective Against Norovirus, Coronaviruses, and Ebola, Lassa, and Nipah Viruses, according to WHO and Global Researchers, Including Singletto Co-Founders
Canadian Healthcare Facilities Magazine: Dyes, Light, and Oxygen by Singletto CEO John Bjornson
Singletto Launches Oxafence Mask Spray in New Zealand
Protective Dye Methylene Blue Plus Light Proven to Inactivate "Hard-to-kill" Norovirus
It all begins with an idea.
Infection Control & Hospital Epidemiology Publishes Drs. Lendvay, Chen, et al. WHO-led DeMaND Study
Top Doctor 2021: Singletto’s Lendvay Named by Seattle Magazine
It all begins with an idea.